Physician profile
Lawrence E Kramer
NPI 1952381295
$9,245.47
in general payments reported to CMS, 2019-2025
39 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $2,210 · 2021: $2,290 · 2022: $1,126 · 2023: $1,109 · 2024: $439 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,567.80 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,045.16 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $926.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.03 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $567.05 | 2020-2022 | |
| Amarin Pharma, INC. | $534.00 | 2019-2021 | |
| Pfizer INC. | $420.09 | 2019-2021 | |
| Novo Nordisk INC | $400.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $307.13 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $305.31 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $274.72 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $214.40 | 2019-2022 | |
| Allergan, INC. | $181.98 | 2020 | |
| Idorsia Pharmaceuticals US INC | $181.87 | 2023 | Quviviq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.